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1. Introduction 
Cancer patients who are undergoing chemotherapy have an increased risk of developing 
cardiovascular complications, and the risk is even greater if there is a known history of heart 
disease. A wide range of chemotherapy agents have been associated with cardiotoxicity. 
Among the serious cardiac complications related to chemotherapy, there are arrhythmias, 
myocardial necrosis causing a dilated cardiomyopathy and vasoocclusion or vasospasm 
resulting in angina or myocardial infarction. 
The anthracyclines and related compounds (doxorubicin, idarubicin, epirubicin, and the 
anthraquinone mitoxantrone) are some of the most frequently implicated agents. 
Anthracyclines, including doxorubicin, are widely used in the treatment of cancer. Although 
topoisomerase II inhibition remains the most persuasive mechanism to explain the 
antitumor activity of anthracyclines, clinically relevant concentrations of anthracyclines 
were shown to induce apoptosis through additional mechanisms that were not bound to the 
topoisomerase II - p53 machinery.  
However, their use is limited by cardiotoxicity and increasing survivors' susceptibility to 
treatment-related complications that can remarkably affect their quality of life. Surviving 
patients have an increased rate of heart failure, coronary artery disease, and 
cerebrovascular accidents compared to the general population. The specific mechanisms 
of anthracycline cardiotoxicity are complex and still remain unclear. Hence, determining 
the factors that may increase propensity to cardiotoxicity is of great importance, as is 
monitoring patients during and after treatment. Additionally, treatment and prevention 
options, such as limiting cumulative dosage, liposomal anthracyclines, and dexrazoxane, 
continue to be explored. 
Liposomal doxorubicin has been developed with the aim of improving the therapeutics 
index of doxorubicin by reducing the drug’s cardiotoxicity. Two liposomal formulations are 
currently available: non-pegylated liposomal doxorubicin (NPLD) (Myocet®, Cephalon, 
USA) and pegylated liposomal doxorubicin (PLD) (Caelix®/Doxil®, Schering-Plough/Orto 
Biothech, USA). 
In this chapter, we will analyze the cardiac complications caused by the use of 
anthracyclines, and the potential benefit of substituting these drugs with their liposomal 
counterpart. Acute and chronic cardiac toxicities, together with risk factors will also be 
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discussed. Guidelines for monitoring and drug discontinuation will be another point to be 
analyzed in this chapter. 
2. Pharmacology 
The anthracyclines represent a broad family of antibiotics that exhibit activity in numerous 
tumours. The first anthracyclines, doxorubicin (DOX) and daunorubicin (DNR), were 
isolated from Streptomyces var. Peucetius; they were shown to be composed of a tetracyclic 
ring system with adjacent quinone-hydroquinone moieties, a short side chain with a 
carbonyl group, and an aminosugar bound to the C-7 of the four-ring system. DOX and 
DNR only differed in the side chain terminus (–CH2OH in DOX vs –CH3 in DNR). Second 
generation anthracyclines, like epirubicin (EPI) and idarubicin (IDA), were obtained after 
minor chemical modifications of DOX or DNR, respectively.  
When injected by standard i.v. infusion, anthracyclines show a rapid distribution phase, a 
high distribution volume at steady state (15 l/kg), a slow elimination phase (successive 
plasma half-lives of  5 minutes, 1 hour and 30 hours). Anthracyclines are excreted mostly 
through bile, which imposes special care in patients with hepatic dysfunction  (Robert & 
Gianni, 1993). In comparison with DOX, EPI is characterized by an unique glucuronidation 
that accelerates its systemic body clearance and imposes administering EPI at doses 1.5 
times higher than those of DOX (Innocenti F et al., 2001). 
Anthracyclines have long been known to kill tumor cells by inhibiting topoisomerase II. 
Anthracyclines act by stabilizing a reaction intermediate in which DNA strands are cut and 
covalently linked to topoisomerase II, eventually impeding DNA resealing. Anthracycline 
intercalation into DNA plays a role in this reaction; in fact, anthracycline rings that do not 
intercalate into DNA probably stabilize the complex between topoisomerase II and the DNA 
that it has nicked (Menna et al., 2008). Anthracycline- and topoisomerase II-mediated DNA 
damage is followed by growth arrest in G1 and G2 and apoptosis. This is usually, but not 
always, relayed by p53 and the consequent induction of the WAF1/CIP1 p21 gene product, 
a strong inhibitor of cyclin-dependent kinases that favour cell cycle progression through the 
G1 to S transition (Minotti et al., 2008).  
Although topoisomerase II inhibition remains the most persuasive mechanism to explain the 
antitumor activity of anthracyclines, clinically relevant concentrations of anthracyclines 
were shown to induce apoptosis through additional mechanisms that were not bound to the 
topoisomerase II - p53 machinery. These mechanisms include, among others, i) the 
activation of neutral sphingomyelinases, followed by ceramide formation and converse 
activation of cell death effectors (c-Jun N-terminal kinase) or down-regulation of survival 
pathways (Akt/protein kinase B) ii), mitochondrial dysfunction, followed by cytochrome c 
release and apoptosome formation iii), induction of lipid peroxidation and formation of 
malondialdehyde-DNA adducts, followed by the reduced activity of cyclin E- and cyclin B- 
associated kinase activities and growth arrest in both p53-proficient and p53-deficient cells 
iv), inhibition of the proteasome, followed by an accumulation of undegraded ubiquinated 
proteins which signal apoptosis. The mechanisms i-iii) are triggered by reactive oxygen 
species (ROS), that are major byproducts of anthracycline metabolism. ROS may also enable 
anthracyclines to damage and shorten telomeres, long sequences of base repeats that 
otherwise would delay cell senescence and apoptosis by preventing the degradation and 
ligation of the end of chromosomes; however, anthracycline-induced telomere damage and 
dysfunction would be relayed to apoptosis through p53 (Minotti et al, 2004).  
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Anthracycline treatment may be accompanied by the acquisition of a resistance phenotype 
through a combination of pharmacokinetic and pharmacodynamic mechanisms. On 
pharmacokinetic grounds, tumor resistance is caused by the reduced accumulation and/or 
an altered distribution of anthracyclines in tumor cells, usually mediated by overexpression 
of drug transporters that belong to the ATP-binding cassette family of proteins and are 
collectively referred to as ABC proteins (P-glycoprotein/Pgp, multidrug resistance protein 
1/MRP1, breast cancer resistance protein/BCRP). On pharmacodynamic grounds, tumor 
resistance may be caused by such diverse mechanisms as topoisomerase II mutation or 
redundancy, overexpression and preferred nuclear localization of proteasome α-type 
subunits (leading to a anomalous degradation of topoisomerase II), genetic deletion or loss-
of-function mutations of p53, overexpression of ROS-detoxifying enzymes, overexpression 
of Bcl-2 (leading to a diminished cytochrome c release), etc. When taken in isolation, 
however, none of these factors would universally predict anthracycline-resistance in a given 
tumor or another (Minotti et al., 2008).  
3. How do anthracyclines damage the heart 
The problem of anthracycline-induced cardiomyopathy and congestive heart failure (CHF) has 
been around for some 40 years. On ultrastructural grounds, all of the approved anthracyclines 
share a pattern of damage that is characterized by loss of myofibrils, dilation of the 
sarcoplasmic reticulum, cytoplasmic vacuolization, swelling of mitochondria, and increased 
number of lysosomes; however, safety threshold may differ from one anthracyclines to 
another. In the case of DOX, the incidence of cardiomyopathy and congestive heart failure 
(CHF) averages below 5% if the cumulative dose did not exceed 400-450 mg/m2 (Swain et al., 
2003) ; EPI induces CHF at doses slightly higher than equiactive to DOX (800-900 mg/m2). 
Safety limits for DNR and IDA are less firmly established because of different regimens and 
schedules adopted in induction or consolidation treatment of myeloproliferative disorders. 
With that said, cardiac events may develop at reportedly safe cumulative doses if patients 
presented with hypertension, arrhythmias, valvular or coronary disease, or metabolic 
disorders; Moreover, children and the elderly are more vulnerable than the young-adult 
(Minotti et al., 2010). Perhaps more importantly, we now know that subthreshold doses of 
anthracyclines, as commonly adopted in many oncologic settings, may cause the development 
of cardiotoxicity months to years after completing chemotherapy, as if “safe doses” of 
anthracyclines primed the heart to a subclinical damage liable to a delayed clinical 
manifestation (Minotti et al., 2010). Mechanisms of anthracycline cardiotoxicity should 
therefore be reconciled with the concept of a lifetime risk of cardiotoxicity.  
Anthracycline cardiotoxicity correlates directly with drug’s peak plasma concentration 
(Minotti et al., 2004) but correlates inversely to the levels and activity of ABC proteins that 
eject drugs from endothelial cells of the blood-heart barrier (Sissung et al., 2011). Once inside 
cardiomyocytes, much of anthracycline toxicity seems to depend on bioactivation events.  
The quinone moiety of anthracyclines undergoes one-electron reduction by a number of 
reductases, primarily located to mitochondria; oxidation of the so-formed semiquinone with 
molecular oxygen regenerates the parent quinone and exposes the cell to higher than 
physiological levels of ROS like superoxide anion (O2.-), hydrogen peroxide (H2O2), and 
hydroxyl radical (.OH). Bimolecular reaction of O2.- with nitric oxide also generates 
peroxynitrite endowed with noticeable prooxidant activities. In comparison to other cell 
types cardiomyocytes are very rich in mitochondria, but relatively poor in ROS-detoxifying 
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enzymes; it follows that cardiomyocytes would readily succumb to a sustained generation 
of ROS that eventually induced sarcomere degradation, mitochondrial dysfunction and 
DNA damage, disruption of cardiac-specific gene expression programs, necrotic or 
apoptotic death (Minotti et al., 2004). This “oxidative stress” hypothesis of cardiotoxicity 
gained popularity over the years and was successfully probed in transgenic mice that 
overexpressed antioxidant defense systems like catalase, mitochondrial manganese-
dependent superoxide dismutase, metallothioneins; Interestingly, however, robust doses of 
antioxidants like vitamin E or N-acetylcysteine neither delayed nor mitigated cardiotoxicity 
induced in patients by cumulative doses of DOX (Minotti et al., 2004). The only compound 
consistently found to be cardioprotective in clinical settings is the iron chelator, 
dexrazoxane. Iron chelation would mitigate free radical reactions that otherwise caused 
cardiotoxicity. Another caveat in the “oxidative stress hypothesis” is the lack of a clear-and-
cut relation with the lifetime risk of cardiotoxicity. Once inside cardiomyocytes 
anthracyclines can diffuse back toward extracellular fluids, making the intracellular drug 
levels decrease to below a threshold of toxic concern (Salvatorelli et al., 2009). Some 
investigators suggested that DOX caused an oxidative mitochondriopathy that self-
maintained after DOX had been cleared from cardiomyocytes; however, self-maintaining 
mitochondriopathy was documented with DOX but not EPI (Lebrecht & Walker, 2007), in 
spite of that EPI clearly retained a potential for inducing cardiotoxicity. On balance, 
anthracyclines do form ROS in the relatively unprotected cardiac tissue, but compelling 
evidence for a cause-and-effect relationship between oxidative stress and chronic 
cardiomyopathy is lacking. 
The lifetime risk of cardiotoxicity from anthracyclines could be better reconciled with their 
conversion to secondary alcohol metabolites, formed after two electron reduction of their 
side chain carbonyl group. Being more polar than their parent drugs, secondary alcohol 
metabolites are poorly cleared from cardiomyocytes and accumulate to become a long-
lasting anthracycline toxic signature in the heart (Menna et al., 2008); times more potent than 
their parent anthracyclines at inactivating Ca2+-handling proteins of the contraction-
relaxation cycle or key regulators of energy metabolism and redox balance, such as 
cytoplasmic aconitase. Therefore, secondary alcohol metabolites may cause cardiotoxicity 
both during and well after the course of chemotherapy.  
In clinical settings, a retrospective study of patients enrolled in the Childhood Cancer 
Survivor Study suggests that the V244M polymorphism of carbonyl reductase 3 associated 
with a higher risk to develop CHF, presumably because the methionine244 isoform of 
carbonyl reductase 3 shows a greater catalytic specificity toward carbonyl substrates (Blanco 
et al., 2008). Most recent reports suggest that gain of function CBR polymorphisms could be 
invoked to particularly explain CHF development in patients exposed to subthreshold 
cumulative doses of anthracyclines . 
There are, of course, some caveats in the alcohol metabolite hypothesis of cardiotoxicity. 
EPI forms fewer amounts of its alcohol metabolite as compared to DOX, which is 
consistent with CHF developing at cumulative doses of EPI higher than equiactive to 
DOX (Salvatorelli et al., 2007).  In contrast, DNR and IDA generate more alcohol 
metabolites than DOX in spite of that their cardiotoxicity was ranked similar to or less 
severe than that of DOX, respectively (Minotti et al., 2004). Once again, the different 
modalities of administration of DNR or IDA in the settings of myeloproliferative disease 
could be invoked to explain such discrepancy.  
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4. How to prevent anthracycline induced cardiotoxicity 
Anthracycline cardiotoxicity coud be prevented by replacing bolus administration with slow 
infusions that generate lower anthracycline plasma peaks and thus mitigate a 
pharmacokinetic determinant of cardiotoxicity. The benefit of replacing bolus 
administration (5-15 min infusion) with slow infusions (24-48 h) is quite evident in adult 
settings but not in pediatric settings. The current thinking is that children are more 
vulnerable by anthracyclines; the protective benefit obtained by lowering plasma peak 
concentrations would therefore be offset by damage due to the longer cardiac exposure to 
anthracyclines (Lipshultz et al., 2002).   
The notion that anthracycline-related cardiotoxicity may develop long after completing 
chemotherapy suggests that drugs used to treat clinically evident cardiotoxicity should be 
used much earlier to protect the heart against subclinical cardiotoxicity. Unfortunately, 
active cardiac prevention by beta-blockers, angiotensin I-converting enzyme inhibitors, or 
angiotensin II receptor blockers, has been explored in only few limited studies. Prophylactic 
commencement of angiotensin I-converting enzyme inhibitors prevented decrements of Left 
Ventricular Ejection Fraction (LVEF) in patients receiving high-dose chemotherapy 
(Cardinale et al, 2006), while prophylactic commencement of angiotensin II receptors 
blockers prevented transient elevations of brain natriuretic peptide in patients receiving one 
cycle of standard-dose chemotherapy for non-Hodgkin lymphoma (Nakamae et al., 2005). 
Unfortunately, prophylactic commencement of cardiovascular medications was not 
prospectively assessed in patients scheduled to receiving multiple cycles of standard-dose 
chemotherapy. The reported protective efficacy of carvedilol, mixed a1-2-b1 blocker, was 
observed in patients treated with anthracycline cumulative doses higher than recommended 
(Kalay et al., 2006) this likely amplified the protective signal of any drug that had been 
administered (Florenzano & Salman, 2007). Outside of these limited exploratory studies, 
prophylactic commencement of cardiovascular medications is uncommon or disregarded 
because of concerns about class-related effects such as hypotension, bradicardia, fluid 
retention, cough, or other discomfort.  
As already mentioned, dexrazoxane was the only compound that consistently proved 
effective in preventing anthracycline-related cardiotoxicity. The chemical structure of 
dexrazoxane consists of a bis-ketopiperazine that diffuses in cardiomyocytes and then 
undergoes stepwise hydrolysis of the two piperazine rings to form one-ring open 
intermediates. This one-ring intermediate hydrolyses to give a diacid-diamide (code-named 
ADR 925) which is structurally reminiscent of EDTA and chelates iron bound to low 
molecular weight cellular ligands or coordinated within 3:1 anthracycline:Fe complexes 
(Minotti et al., 2004). When administered by intravenous push or slow infusion some  15 to 
30 min before DOX at dose ratios up to 10:1 to DOX, dexrazoxane did not interfere with 
DOX distribution or metabolism or excretion, but reduced the incidence of cardiotoxicity. In 
a randomized clinical trial, women with metastatic breast cancer who received dexrazoxane 
prior to DOX could be treated with more cycles and higher cumulative doses of DOX (700-
1,000 mg/m2 or more) than patients in the control group. Moreover, cardiac protection was 
observed in patients with or without risk factors such as e.g., prior chest wall irradiation 
(reviewed in Minotti et al., 2004). As a matter of fact, the pharmacological properties and 
clinical readouts of dexrazoxane have been widely challenged. In the pharmacological field, 
there have been reports that dexrazoxane could protect by mechanisms other than iron 
chelation, like e.g., inhibition of topoisomerase II-mediated formation of DNA double-
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strand breaks in cardiomyocytes (Lyu et al., 2007). Accordingly, preclinical studies showed 
little or no cardiac protection by dexrazoxane analogues that chelated iron but failed to 
inhibit toposomerase II (Sterba et al. J Pharmacol Exp Ther 2006). In the clinical setting, the 
risk/benefit ratio of dexrazoxane was questioned in terms of hemathologic toxicities and 
interference with anthracycline activity.  An exacerbation of anthracycline-related 
myelotoxicity (usually in the form of grade 3 or 4 neutropenia) is a well- known 
complication of the use of dexrazoxane, but other studies raised a concern that children 
treated with dexrazoxane were at a higher risk for second malignancies including, among 
others,  acute myelogenous leukaemia and myelodysplastic syndrome. This latter concern 
was dispelled by two authoritative studies of childhood cancer survivors who had been 
randomized to receive anthracyclines with or without dexrazoxane as cardioprotectant 
(Barryet al., J Clin Oncol. 2008; Vrooman et al., Eur J Cancer. 2011). Other concerns were 
raised in relation to a possible interference of dexrazoxane with anthracycline activity. One 
single study suggested that dexrazoxane reduced response rates in women who received 
DOX for the treatment of advanced breast cancer (Swain et al., J Clin Oncol 1997) but many 
other clinical studies showed that this was not the case in either pediatric or adult settings 
(Swain and Vici, J Cancer Res Clin Oncol. 2004; van Dalen et al., Cochrane Database Syst 
Rev. 2011). In spite of the overwhelming evidence for its safety and preventative activity in a 
number of oncologic settings, the American Society of Clinical Oncology, Chemotherapy, 
and Radiotherapy Expert Panel maintained and recommended using dexrazoxane only in 
patients who had received more than 300 mg of DOX/m2 and could benefit from continuing 
on DOX or EPI (Schuchter et al., 2002). It is our opinion that dexrazoxane should be used 
with less restrictions; current limitations to using it in a prophylactic manner are not 
supported by available evidence.  
In a similar manner, oncologists should be encouraged to use liposomal formulations of 
DOX. These formulations approach very high peak plasma levels and longer circulating 
time than conventional DOX but release little or no free anthracycline in the bloodstream.  
Moreover, the liposomes are small enough to diffuse through the discontinuous “leaky” 
endothelium of tumors, but they are big enough not to diffuse through the normal 
microvasculature of the heart. Liposomal formulations therefore deliver high amounts of 
DOX in tumors but not in the heart. One liposomal DOX (Caelyx®) has polyethylene glycol 
embedded in the lipid layers; another formulation (Myocet®) adopts an uncoated liposome. 
Regardless of obvious pharmacokinetic and toxicokinetic differences between the two 
formulations, both proved remarkably cardiac tolerable and allowed administering high to 
very high cumulative doses of anthracycline. in a number of clinical settings. A recent 
Cochrane Intervention Review raises caution against using liposomal doxorubicin in 
pediatric settings or in patients diagnosed with leukaemia, but it is quite strong in 
concluding that liposomal formulations should be favoured in adults with a solid tumor 
(van Dalen et al., 2010). Despite this authoritative recommendation, clinical use of liposomal 
anthracycline formulations remains quite limited, primarily because of cost-related 
concerns. It is our opinion that liposomal doxorubicin should remain a must in certain 
approved settings (like e.g., ovary cancer in the case of Caelyx) and first choice in any other 
patients presenting with cardiovascular risk factors (as it is the case for Myocet in high risk 
or older patients with non Hodgkin lymphoma) (Visani & Isidori, 2011). 
Preventing the  risk of anthracycline-related cardiotoxicity during the lifetime means to 
reshape the pharmacological management of cancer survivors. Preexisting comorbidities or 
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unfavorable lifestyle choices (hypertension, diabetes, hyperlipidemia, reduced physical 
activity) had long been known to increase the risk of cardiotoxicity in patients scheduled to 
receiving anthracyclines. The available evidence suggests that this picture should also be 
viewed the other way around. In comparison to siblings or age-matched subjects from the 
general population, previously healthy cancer survivors tend in fact to develop more 
comorbidities or to reduce physical activity (De Bruin et al., 2009; Jones et al., 2007). It 
follows that sublinical cardiotoxicity from “safe doses” of anthracyclines may progress to 
symptomatic events by overlapping with risk factors that matured after ending 
chemotherapy. This is the so-called multiple-hit hypothesis, according to which late onset 
cardiotoxicity originates from pharmacological and non pharmacological sequential injuries 
(Minotti et al, 2010). These concepts call for a new dimension of preventative cardiology, in 
a sense that in cancer survivors any comorbidity or unfavourable lifestyle choice should be 
treated earlier or more vigorously than in the general population.  
5. Monitoring 
There is no universally accepted guideline for monitoring patients receiving anthracyclines. 
Table I provides a tentative schedule that follows on suggestions by Ewer and colleagues 
mainly based on widely used criteria such as cumulative dose, time elapsed after 
chemotherapy, presence or absence of cardiovascular risk factors or preexisting cardiac 
disease, concerns (or symptoms) calling for unscheduled visits and cardiological inspection, 
dosability in any clinical center (measurements of LVEF only).  
 
Planned 
Cumulative 
Dose 
(mg/m2) 
During treatment After  treatment 
No risk factors or 
Preexisting Cardiac 
Disease 
One or more risk 
factors, Preexisting 
Cardiac disease 
No risk factors or 
Preexisting Cardiac 
Disease 
One or more risk 
factors, Preexisting 
Cardiac disease 
Baseline yes yes   
<300 
At the physician’s 
discretion 
Recommended  
after two-three 
cycles 
Approx 1, 6, and 12 
months after ending 
therapy, and then 
every two years 
unless symptoms 
occur 
Approx 1, 6, and 12 
months after ending 
therapy, and then 
every year unless 
symptoms occur 
300-450 
At the physician 
discretion; 
recommended 
anytime patients 
report on symptoms 
Recommended 
every two cycles 
Approx 1, 6, and 12 
months after ending 
therapy, and then 
every year unless 
symptoms occur 
Approx 1 month 
after ending  
therapy, and then 
every six months 
unless symptoms 
occur 
>450 
Recommended at 
midtherapy or 
earlier if symptoms 
occur 
Recommended 
every two cycles or 
more often if 
symptoms occur 
Approx 1 month 
after ending  
therapy, and then 
every six months 
unless symptoms 
occur 
Approx 1 month 
after ending  
therapy, and then 
every six months 
unless symptoms 
occur 
Table 1. General principles for monitoring LVEF in patients receiving doxorubicin. Modified 
after Ewer and Benjamin  (2006). 
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Whereas the reported timetable is intrinsically correct and doable in everyday clinical 
practice, there are at least two disturbing points that need to be kept in mind if one wished 
to improve the caring of cancer patients and survivors. First, we now know that as little as 
100 mg of DOX/m2 may cause an increased risk of asymptomatic abnormalities at non-
invasive cardiac tests, whereas 270 mg of DOX/m2 introduces a measurable 4.5-fold excess 
risk of such abnormalities (Hudson et al, 2007). The second point  is that dilative 
cardiomyopathy and systolic failure (reduced LVEF) have been considered for long time the 
only (or prevailing) clinical phenotypes of chronic cardiotoxicity from anthracyclines. 
Therefore, serial measurements of LVEF (whether by echocardiography or MUGA) have 
been adopted to measure the cardiac function of patients treated with anthracyclines. 
Keeping this in mind, we now know that asymptomatic diastolic dysfunction is seen in 
many cancer survivors with a history of prior exposure to anthracyclines. Anthracyclines, in 
fact, could cause diastolic elevated [Ca2+]I and impaired left ventricle relaxation (stiffness) by 
a number of mechanisms (inhibition and/or reduced expression levels of the Ca2+-ATPase 
that sequesters Ca2+ in sarcoplasmic reticulum, inhibition of the energy build-up that assists 
Ca2+ loading in mitochondria, inappropriate opening of the Ca2+-gated Ca2+ release channel 
of the sarcoplasmic reticulum (ryanodine receptor 2) (Minotti et al, 2004). Long lasting 
diastolic dysfunction eventually increases interstitial pressure, thereby diminishing 
coronary conductance and causing ischemia that further aggravates Ca2+ overload and left 
ventricle wall tension (Hale et al., 2008). Reciprocal interactions between diastolic 
dysfunction and ischemia may remain asymptomatic for many years but eventually surface 
in the form of symptomatic ischemic disease and myocardial infarction. The risk of 
myocardial infarction in previously nonischemic Hodgkin’s lymphoma survivors therefore 
correlated with their prior exposure to anthracyclines (Swerdlow et al., 2007). Furthermore, 
diastolic dysfunction and reduced coronary conductance would render the heart more 
vulnerable by comorbidities that diminish coronary flow or increased oxygen demand, like 
e.g. premature atherosclerosis or hypertension. All such concepts call for reshaping current 
modalities of follow up of cancer survivors. Serial measurements of LVEF should no longer 
be considered adequate to identify patients at risk for symptomatic cardiac events. 
Moreover, careful inspection of diastolic function (e.g., transmitral flow) is equally 
important and much needed, not to mention myocardial perfusion imaging techniques that 
show hypoperfusion under stress conditions. These approaches are less doable in clinical 
practice, leaving many patients with normal LVEF at risk for sudden or slowly developing 
cardiac events.  
Current limitations in the monitoring of patients at risk for anthracycline related 
cardiotoxicity could be obviated by measuring pre- and post- infusional levels of circulating 
troponin (TnI), marker of toxic or ischemic cardiomyocyte necrosis. Persistent elevations of 
TnI were shown to anticipate LVEF decrements and other cardiac events in otherwise 
asymptomatic childhood cancer patients (Lipshultz et al., 1997) or in adults receiving high-
dose chemotherapy (Cardinale et al., 2006). More recently, elevations of TnI  were shown to 
anticipate LVEF decrements in women who had received sequential adjuvant chemotherapy 
and immunologic treatment with the anti-Erbb2 monoclonal antibody trastuzumab for the 
treatment of Erbb2+ early breast cancer  (J Clin Oncol., 2010, 28:3910-6). Unfortunately, TnI 
measurements are uncommon outside of limited exploratory studies; there is a lack of 
studies that prospectively evaluated TnI in large cohort of patients and firmly established 
laboratory ranges that should guide the physicians in making decisions such as adjusting 
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the dose of anthracycline or commencing prophylactic cardiovascular medications. Similarly 
uncommon is the measurement of circulating natriuretic peptides, markers of left 
ventricular diastolic tension. On treatment elevations of natriuretic peptides were reported 
to anticipate chemotherapy-induced diastolic dysfunction, but such elevations were seen in 
patients treated with high-dose chemotherapy or in patients receiving just one cycle of 
standard-dose chemotherapy (Gianni et al., 2008,  J. Clin. Oncol. 26; Nakamae et al., 2005). 
There is little information on the prognostic value of natriuretic peptides elevations during 
the course of cumulative standard-dose chemotherapy and at follow-up. 
6. Liposomal formulations of doxorubicin 
Daunorubicin (DNR) as the cell cycle non-specific anthracycline antibiotics is highly 
effective in treating a wide range of cancer diseases [5-7]. Its antineoplastic mechanisms are 
through DNA topoisomerase II inhibition, DNA intercalation, RNA synthesis inhibition, cell 
membranes interaction, free radicals production and induction of apoptosis [8-10]. 
However, the clinical use of daunorubicin is hampered by two major problems: 
cardiotoxicity [11] and drug resistance, as daunorubicin is a substrate for P-glycoprotein 
(MDR1; ABCB1) [12] and breast cancer resistance protein (BCRP;ABCG2) [13]. This limits of 
standard doxorubicin have moved forward the development of new liposomal formulations 
of the drug, which gained increasing interest in the therapy of onco-hematological 
malignancies and, in particular, for the treatment of breast cancer and B-cell lymphomas. In 
the early 1980s, liposomes were discovered to be good anthracycline carriers, reducing 
toxicity while retaining potent antitumor activity and therefore improving the therapeutic 
index of anthracyclines [14]. Liposomal formulations of doxorubicin have indeed been 
developed with the aim of improving the therapeutic index of doxorubicin by reducing the 
drug’s cardiotoxicity. Nevertheless, liposomal conjugation of doxorubicin results in 
preferential distribution of the drug in the tumor compared with normal tissue. 
Two liposomal formulations are currently available: non-pegylated liposomal doxorubicin 
(NPLD) (Myocet®, Cephalon, USA) and pegylated liposomal doxorubicin (PLD) 
(Caelix®/Doxil®, Schering-Plough/Orto Biothech, USA) 
NPLD is a liposome encapsulated formulation of doxorubicin, which differs from 
pegylated liposomal doxorubicin, as well as from unencapsulated, conventional 
doxorubicin, resulting in an alteration in the pharmacokinetics and biodistribution. This 
results in a higher area under the curve, a smaller volume of distribution and a 
preferential distribution to liver, spleen, and lymphatics, when compared with 
conventional doxorubicin. Pre-clinical studies comparing equal doses of liposome-
encapsulated doxorubicin and conventional doxorubicin showed that the use of 
nonpegylated liposomal doxorubicin resulted in a significantly lower cardiac and 
gastrointestinal toxicity, with similar anti-tumor efficacy. 
The other liposomal compound, pegylated liposomal doxorubicin (PLD) (Caelix®/Doxil®, 
Schering-Plough/Orto Biothech, USA), is a liposomal formulation with a distinct 
pharmacokinetic profile characterized by an extended circulation time and a reduced 
volume of distribution [22]. Biodistribution animal studies indicate superior accumulation of 
PLD into various implanted mouse-human tumors, with an augmentation of liposomal drug 
tumor levels compared with free drugs [22]. The extended circulation time of pegylated 
liposomes and their ability to extravasate through the leaky vasculature of tumors results in 
the increased delivery of liposomal drug and/or radiotracers to the tumor site in patients 
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with cancer. Pegylated liposomal doxorubicin has been approved for clinical use in a variety 
of cancer types due to its antitumor efficacy. However, the safety profile needs further 
improvement, as long as hand-foot syndrome remains a dose-limiting toxic effect of Doxil, 
maybe due to the considerable amount of drug being delivered to the skin owing to the 
drug’s long circulation in the bloodstream. 
7. Non-Pegylated Liposomal Doxorubicin (NPLD) 
NPLD is a doxorubicin citrate complex encapsulated in a liposome, an aqueous dispersion 
of egg Phosphatydilcholine 
and cholesterol, sterile, non-pyrogenous that traps doxorubicin by pulling it into the interior 
of the vesicle (TLC D-99 model) by the generation of an electropotential across the liposome 
membrane. This mechanism for remote loading involves the generation of a pH gradient 
between the inside and the extraliposomal buffer. At the end of the encapsulation process, 
the ratio of doxorubicin:lipid in NPLD is approximately 1:4 and the pH is in the range of 
5.5–6.5. The maximum activity of doxorubicin and other anthracyclines manifests itself in 
the S phase of the cellular cycle. 
The encapsulation of a cytostatic agent within a macromolecular vector such as a liposome 
reduces drastically its distribution volume, diminishing its diffusion in the organism and thus 
the toxicity for healthy tissues while increasing the concentration within the neoplastic tissue. 
In ideal conditions the drug can be transported in the circulatory system within the liposome’s 
aqueous space and arrives to the site of the tumor in active form. Encapsulation in a liposome 
means the drug is protected from inactivation while in the blood stream and furthermore its 
diffusion through the healthy endothelium is limited, while it can diffuse through tumoral 
endothelium which would present discontinuities. Thus, NPLD should preferentially direct 
doxorubicin away from sites of potential toxicity, but leaves the tumor exposed. 
7.1 Non-pegylated liposomal doxorubicin in breast cancer 
NPLD was designed to reduce the cardiotoxicity of doxorubicin while preserving its 
antitumor efficacy. In the early 2000, the safety and efficacy of NPLD was tested in cancer 
patients, after the demonstration of a significantly lower cardiac and gastrointestinal 
toxicity, with similar anti-tumor efficacy showed by NPLD in pre-clinical studies. 
The first studies were conduced in breast cancer patients. These phase III, randomized, 
multicenter trials were designed to test the hypothesis that NPLD, alone or in combination 
with other drugs, would result in significantly less cardiac toxicity than the same dose and 
schedule of conventional doxorubicin and other drugs, while providing comparable 
antitumor efficacy in first-line treatment of metastatic breast cancer.  
Batist et al (Batist et al., 2001) randomized 297 patients with MBC and no prior 
chemotherapy for metastatic disease were randomized to receive either 60 mg/m2 of NPLD 
or conventional doxorubicin (A), in combination with 600 mg/m2 of cyclophosphamide (C), 
every 3 weeks until disease progression or unacceptable toxicity. Antitumor efficacy of MC 
versus AC was comparable: objective response rates, 43% versus 43%; median time to 
progression, 5.1% versus 5.5 months; median time to treatment failure, 4.6 versus 4.4 
months; and median survival, 19 versus 16 months (Batist et al., 2001).  
Cardiotoxicity was a primary end point parameter in all treated patients (Batist et al., 2001). 
Cardiac toxicity, sufficient for removal of a patient from study, was defined as a decrease in 
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resting LVEF of ≥ 20 ejection fraction (EF) units from baseline to a final value of ≥ 50%, or a 
decrease of ≥ 10 EF units from baseline to a final value of less than 50%, or clinical evidence 
of CHF. LVEFs were assessed using serial Multigated blood-pool imaging (MUGA) scans, 
which have been shown to be a reliable and serially reproducible method of evaluating 
cardiac function in patients receiving anthracycline therapy. 
To ensure accuracy and objectivity, each center was required to have its equipment and 
methodology used for MUGA scans reviewed and certified by a cardiologist at the Core 
Laboratory at Yale University before enrolling patients. During the trial, all MUGA scans 
were sent to the Core Laboratory at Yale, where they were read by the same cardiologist 
blinded to the patient’s treatment (Batist et al., 2001). To minimize the risk of CHF, all scans 
were read in real time and results provided to the site before the next scheduled dose of 
anthracycline therapy. CHF was determined on the basis of a treatment-blinded review of 
records from patients for whom the investigator had made a diagnosis of CHF, as well as 
patients who had a LVEF of ≤ 30%. LVEF ≤ 30% was selected as the cutoff because these 
patients are at significant risk for CHF (Batist et al., 2001).  The blinded review was 
conducted by a second cardiologist at Yale University noted for his expertise in 
doxorubicin-induced cardiotoxicity. All MUGA scan data were interpreted and LVEF values 
were estimated at a core laboratory on a blinded basis. Nine patients (6%) treated with MC 
developed protocol-defined cardiotoxicity compared with 33 patients (21%) treated with AC 
(log-rank P = .0001). Five cases of CHF, all in the AC arm (log-rank P = .02), were observed 
after cumulative lifetime doses ranging from 360 to 480 mg/m2. Four of the five patients 
with CHF were anthracycline-naive before this study; one patient had 240 mg/m2 of prior 
adjuvant doxorubicin. All other patients with cardiotoxicity had an asymptomatic decrease 
in LVEF of ≥ 10 EF units from baseline to a final value less than 50%. The estimated (Kaplan-
Meier) median cumulative lifetime dose of doxorubicin at the first occurrence of protocol-
defined cardiac toxicity was more than 2,220 mg/m2 for the MC arm versus 480 mg/m2 for 
the AC arm. The hazard ratio of 4.8 shows that patients treated with MC were 80% less 
likely to develop cardiotoxicity with respect to patients treated with AC.  
Similarly, there was a highly significant difference in the time to onset of cardiotoxicity 
when measured from the start of protocol therapy. The estimated median onset of protocol-
defined cardiotoxicity was more than 22 months for MC versus 10 months for AC (log-rank 
P = .0003).  There was a gradual increase in the median change from baseline LVEF to the 
last posttreatment LVEF among patients treated with either regimen, but this was more 
pronounced in the AC-treated group (Batist et al., 2001).  
In the subset of patients with recognized risk factors for cardiac toxicity, the hazard ratio 
was increased to 16, indicating that these patients were more than 90% less likely to develop 
cardiac toxicity with MC relative to AC. Four percent of MC-treated patients developed a 
protocol-defined cardiac event versus 22% of AC-treated patients (Batist et al., 2001). The 
median lifetime cumulative dose of doxorubicin at onset was 480 mg/m2 for AC versus 
more than 2,220 mg/m2 for MC (P = .0001) (Batist et al., 2001). Four of the five patients with 
CHF were in this subgroup with increased risk of cardiac toxicity (Batist et al., 2001).  
In conclusion, the improved therapeutic index for NPLD predicted by the preclinical data 
and indicated by the phase I/II clinical trials was confirmed in this phase III, randomized, 
multicenter trial. Statistically significantly fewer patients treated with NPLD in combination 
with cyclophosphamide experienced cardiac toxicity defined by reductions in LVEF or 
clinical CHF (Batist et al., 2001). 
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Another interesting study was carried on by Harris et al (Harris et al, 2002). Two hundred 
twenty-four patients with MBC and no prior therapy for metastatic disease were 
randomized to receive either TLC D-99 (75 mg/m2) or doxorubicin (75 mg/m2) every 3 
weeks, in the absence of disease progression or unacceptable toxicity. The primary efficacy 
endpoint was response rate. The primary safety endpoint was cardiotoxicity. 
Electrocardiograms and MUGA scans were done at baseline, and after reaching a lifetime 
cumulative doxorubicin dose of 300, 400, 500 mg/m2, and before each subsequent dose, at 
off-study, and at 3-month follow-up. All MUGA scan data were transferred electronically to 
a core laboratory for blinded interpretation and estimation of LVEF (Harris et al, 2002). 
Before the first interim analysis, endomyocardial biopsies were performed at a selected 
number of institutions after lifetime cumulative doxorubicin dose of 425 mg/m2. All 
patients whose LVEF declined by greater than 10% to a value of greater than or equal to 
50%, or by greater than 6% to a value of less than 50% were to have cardiac biopsies 
regardless of lifetime cumulative doses (Harris et al, 2002). All biopsies were read by a core 
pathologist, and the results were scored according to the Billingham scale. The purpose of 
biopsies was to validate the results of MUGA scans. After the first interim analysis, it was 
determined that MUGA scans were adequate to monitor cardiac function and cardiac 
biopsies were discontinued (Harris et al, 2002). All MUGA scan data were sent to an 
independent central laboratory for estimation and interpretation of LVEF values without 
knowledge of treatment arm.  
Cardiac events, sufficient for removal of a patient from study, were more than twice as 
frequent in doxorubicin-treated patients than TLC D-99–treated patients (29% vs. 13%, log-
rank P = 0.0001) (Harris et al, 2002). With the increasing lifetime cumulative dose of 
doxorubicin and TLC D-99, there was a gradual increase in the median change from baseline 
LVEF to the first post-treatment LVEF among patients treated with either agent, but this was 
more pronounced in the doxorubicin group (Harris et al, 2002). A Kaplan–Meier estimate of 
the probability of the first onset of a cardiac event as related to the lifetime cumulative dose 
of doxorubicin or TLC D-99 showed that risk of cardiotoxicity was much higher with 
doxorubicin treatment than TLC D-99 (HR = 3.56) (P = 0.0001) (Harris et al, 2002). Two 
patients (2%) on TLC D-99 developed clinical CHF. One patient, after 13 cycles of TLC D-99 
and a cumulative dose of 1110 mg/m2, had a decrease of 14 EF units in her LVEF to 46% and 
was taken off-study. Two months after the last dose she presented with shortness of breath 
and bilateral pleural effusions and was hospitalized for CHF. Another patient, with prior 
adjuvant doxorubicin dose of 290 mg/m2 and prior chest wall irradiation, received five 
cycles of TLC D-99 for a total lifetime doxorubicin dose of 785 mg/m2, and went off-study 
for PD. Four months after the last dose, a MUGA scan showed a LVEF of 46% (a 16-point 
decrease from baseline). Later, the patient received five cycles of a mitomycin plus 
mitoxantrone, and 11 months after the last study treatment she received a diagnosis of CHF 
(Harris et al, 2002). Nine patients (8%) on doxorubicin developed clinical CHF at lifetime 
doses of 525–765 mg/m2. Three patients had CHF within 30 days of the last dose of study 
treatment, including one who died of CHF after 585 mg/m2. All nine cases were attributed 
to study drug treatment (Harris et al, 2002). 
Before the first interim analysis, 51 patients were treated at 8 participating institutions 
performing endomyocardial biopsies. Of those, 36 patients qualified for the procedure, and 
all 36 patients had cardiac biopsies. All biopsies were read by a core pathologist, blinded to 
treatment assignment, and the results were scored according to the Billingham scale. There 
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was a significant difference between the two treatment groups favoring TLC D-99 and the 
number of patients who had a score of greater than or equal to 2.5 (26% vs. 71%; P = 0.02) 
(Harris et al, 2002). 
Regarding efficacy, the overall response rate was 26% in both treatment groups. The 
median TTP was 2.9 months on TLC D-99 versus 3.1 months on doxorubicin. Median 
survival was 16 versus 20 months with a non significant trend in favor of doxorubicin  
(P = 0.09). 
In another randomized study, Chan et al tried to ascertain the efficacy and tolerability of 
NPLD and epirubicin combined with cyclophosphamide in the first-line treatment of 
patients with metastatic breast cancer (Chan et al., 2004). One hundred and sixty 
anthracycline-naïve metastatic breast cancer patients were randomised to receive NPLD (M; 
75 mg/m2) or epirubicin (E; 75 mg/m2) in combination with cyclophosphamide (C; 600 
mg/m2), every 3 weeks for up to eight cycles. Cardiotoxicity was low in both treatment 
groups: nine patients on MC and eight on EC had asymptomatic LVEF reductions at 
comparable cumulative doses . For MC there were two cases at 100–299 mg/m2, four at 300–
399 mg/m2 and three at 500–599 mg/m2; for EC there was one case at 200–299 mg/m2, four 
at 300–399 mg/m2 and three at 400–499 mg/m2. There was no clinical evidence of CHF in 
any patient. Overall response rates were 46% and 39% for MC and EC treatment, 
respectively (P=0.42). MC was superior to EC with respect to median time to treatment 
failure (5.7 versus 4.4 months; P=0.01) and median time to disease progression (7.7 versus 
5.6 months; P=0.02). Median survival times were 18.3 and 16.0 months for MC and EC, 
respectively (P=0.504). Unsurprisingly, the results from this study (Chan et al., 2004) 
suggested that, at equimolar doses, in combination with cyclophosphamide, NPLD has 
modest but significant advantages over epirubicin for some efficacy end points and a non-
significant trend towards improvement in others. Given the well established correlation 
between dose and therapeutic effect for doxorubicin, and in light of the uncertainty 
surrounding the optimal therapeutic dose of epirubicin, NPLD offers clinicians the 
opportunity to make clinical use of a drug that combines the dose/effect reliability of 
doxorubicin with the level of safety provided by epirubicin.  
In conclusion, two studies (Batist et al., 2001; Harris et al., 2002; Chan et al, 2004) clearly 
demonstrated reduced cardiotoxicity of NPLD when compared to standard doxorubicin, 
with a superimposable antitumor efficacy of the two drugs. The third study showed a trend 
of higher efficacy fot NPLD with respect to epirubicin, with equal cardiotoxicity. 
7.2 Non-pegylated liposomal doxorubicin in non-Hodgkin lymphoma 
The first study testing the safety and efficacy of NPLD in non-Hodgkin lymphoma NHL 
(AIDS-related) was conducted by Alexandra Levine and coworkers in 2004 (Levine et al., 
2004). The study enrolled 24 patients with newly diagnosed AIDS-related NHL (median age: 
43 years). Sixty-seven percent of patients had a high or high-intermediate International 
Prognostic Index (IPI) scores at diagnosis. Serum LDH was high in 17 patients (71%). A total 
of 21 patients (88%) had extranodal disease, and 12 patients (50%) had 2 or more sites of 
extranodal involvement.  
The primary objective of the study was to evaluate the safety and efficacy of NPLD when 
substituted for doxorubicin in the CHOP in patients with newly diagnosed AIDS-related 
non-Hodgkin’s lymphoma (AIDS-NHL). NPLD at doses of 40, 50, 60, and 80 mg/m2 was 
given with fixed doses of cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2) and 
www.intechopen.com
  
Cardiomyopathies – From Basic Research to Clinical Management 
 
634 
prednisone (40 mg/m2) every 21 days. The maximum tolerated dose (MTD) of NPLD was 
defined as the dose at which less than half of the patients on a cohort experienced a dose-
limiting toxicity. No dose escalations were allowed in individual patients. The MTD of 
NPLD was not reached at the 80 mg/m2 dose. As a high complete response (CR) rate was 
seen at all dose levels, a dose of 50 mg/m2 of NPLD was chosen for the phase II portion of 
the trial, which was expanded to a total of 24 patients, including 10 on the initial phase I 
dose-escalation portion. All patients received highly active antiretroviral therapy while on 
chemotherapy.  
The results of the study were encouraging. No dose-limiting toxicities were observed at any 
level, with myelosuppression being the most frequent toxicity (grade 4 neutropenia in 75% 
of patients, neutropenic fever in 12% and neutropenic sepsis in 8%). Overall response rate 
was 88%, with a CR rate of 75%, and a partial response (PR) rate of 13%. The median 
duration of CR was 15.6 months (range, 1.7 to 43.5 months).  
Moreover, 16 out of 24 AIDS-related NHL patients were evaluated for multidrug resistance 
(MDR-1) expression on their hystological samples. The Authors demonstrated that this 
NPLD-based regimen was equally effective in both MDR-1–positive and MDR-1–negative 
cases. The Authors postulated that the efficacy of this regimen was eventually related to the 
ability of NPLD to overcome excessive drug efflux due to P-gp (MDR-1) overexpression. 
The MDR-1 expression did not correlate with response in this study, suggesting that NPLD 
might evade this resistance mechanism. 
In terms of potential cardiac toxicity, left ventricular ejection fraction (LVEF) was obtained 
at baseline and at study termination in 19 patients. No patient developed a decline in LVEF 
to below normal (45%). Fourteen patients had no significant change in LVEF over time, 
while 5 patients (26%) experienced a 10% or greater decline, though their LVEF values still 
remained within normal range. None of these five patients had any signs or symptoms of 
cardiac dysfunction, and the values returned to baseline levels in the two patients who had 
follow-up cardiac studies performed, 3 months after completion of chemotherapy. 
Starting from that background, the same group of the Keck School of Medicine designed in 
2006 a phase I-II trial to evaluate the safety of the same regimen (NPLD, cyclophosphamide, 
vincristine, and prednisone every 21 days) in the treatment of newly diagnosed aggressive 
NHL patients (Tulpule et al., 2006). 
Forty-seven patients (median age: 55 years) were enrolled in the study. The vast majority of 
the patients had diffuse large B-cell NHL (37/47). Liposomal doxorubicin at doses of 40 
mg/m2, 50 mg/m2, 60 mg/m2, and 80 mg/m2 was given with fixed doses of 
cyclophosphamide (750 mg/m2), vincristine (1.4mg/m2) and prednisone (40 mg/m2). 
Chemotherapy cycles were repeated every 21 days.  
No dose-limiting toxicities were observed at any level. Reversible grade 3/4 neutropenia 
was the most common toxicity (95.8%). Most non-hematologic side effects were nausea, 
vomiting fatigue and fever and were primarily grade 1/2 in severity. Stomatitis of mild or 
moderate severity was reported in 23% of patients. 
Two out of 47 patients (4%) developed clinically silent cardiac toxicity, with a decline in 
LVEF of 20% each. None of the patients presented any symptoms of cardiotoxicity. The 
decline in LVEF occurred in one patient after a cumulative NPLD dose of 240mg/m2 and 
in the other one after a cumulative NPLD dose of 640 mg/m2. In both patients the 
declines returned to baseline 2 months and 6 months from discontinuation of NPLD, 
respectively. 
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Complete remissions were documented in 31 of 46 evaluable patients (67.4%) and partial 
remissions in 7 (15.2%), for an overall major response rate of 82.6%. Responses were attained 
after a median of 4 cycles of therapy. Patients with T-cell lymphomas fared poorly with this 
regimen, with none of them achieving a CR lasting more than 6 months. 
The median duration of complete remission was 27.7 months (range, 2.4 months to 59.8 
months). Reported median follow-up was 3.1 years. Median survival was not reached at the 
time of publication. The 2-year estimated overall suvival (OS) probability was 65% (95% CI, 
50-77%), with a 3-year estimated OS probability of 59% (95%CI, 44%-73%). Nineteen patients 
had died at the time of publication. 
Regarding the relationship between MDR-1 expression and outcome, MDR-1-related p-
glycoprotein expression was assessed in lymphoma tissues from 27 patients. Eight patients 
(30%) was MDR-1 positive at diagnosis. No difference in CR rates were observed when 
comparing patients whose tumors expressed MDR-1 versus those who did not (63% in 
MDR-1-positive and 74% in the MDR-1-negative lymphomas, P = 0.66), indicating that 
NPLD might overcome MDR-1 in vivo.  
Rigacci and collaborators (Rigacci et al., 2007) designed a prospective study to assess the 
efficacy and safety of the combination of NPLD with cyclophosphamide, vincristine, 
prednisone and Rituximab (R-COMP) in patients with aggressive non-Hodgkin’s B-cell 
lymphomas and concurrent cardiac disease or pre-treated with anthracyclines. 
Twenty-one patients were selected for the presence of cardiac comorbidity and/or previous 
treatment with anthracycline-based regimens. NPLD at a dose of 50 mg/m2 was 
administered in association with cyclophosphamide (750 mg/m2), vincristine (1.4mg/m2), 
prednisone (40 mg/m2) and rituximab (375 mg/m2) every 21 days for 4 to 6 cycles unless 
progression or unacceptable toxicity occurred. CR rate was 76%, whereas PR rate was 14%, 
with an overall response rate (ORR) of 90%. Two patients (10%) did not respond to therapy. 
After a median follow-up of 13 months (range 2–36 months), 2/16 CR patients relapsed, 
with a cumulative disease-free survival (DFS) rate of 78%. 
Regarding toxicities, the Authors observed only a congestive heart failure (CHF) in one 
patient, among a total of 115 chemotherapy cycles administered. LVEF was evaluated 
after the 3rd cycle and at the end of treatment in all but one patient, who developed CHF 
with LVEF 20% after the first cycle of R-COMP. Between the 20 evaluable patients, 
median LVEF was 60% (range 38%–74%) after three cycles and 60% (range 40%–69%) at 
the end of the treatment. There was no significant difference between LVEF at baseline, 
after the 3rd cycle, and at the end of study in patients with cardiac comorbidity (52, 58 
and 60%, respectively), in those without cardiac diseases (62, 61 and 60%, respectively) 
and in those previously treated with anthracyclines. Patients were evaluated every 6 
months after the end of the study. Among the 15 patients who were followed-up for at 
least 12 months after the end of therapy, none of them presented any cardiac dysfunction 
or significant decrease of LVEF. 
The Authors stated that Rituximab plus NPLD-based regimen was well tolerated and highly 
effective in inducing clinical responses in this group of patients at high risk for cardiac 
toxicity or previously treated with anthracyclines. The tolerability profile was  favorable, 
with a low incidence of cardiac events (1/21 patients).  
Visani and coworkers (Visani et al., 2008) conduced a pilot study to assess the toxicity and 
efficacy of the combination of NPLD with cyclophosphamide, vincristine, prednisone and 
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Rituximab (R-COMP) in frail and elderly patients with aggressive non-Hodgkin’s B-cell 
lymphomas. 
NPLD at a dose of 50 mg/m2 was administered in association with cyclophosphamide 
(750 mg/m2), vincristine (1.4mg/m2), prednisone (40 mg/m2) and rituximab (375 
mg/m2) every 21 days for 4 to 6 cycles unless progression or unacceptable toxicity 
occurred. 
Twenty frail patients (median age: 73 years), as defined by Balducci & Extermann (Balducci 
& Extermann,2000) with diffuse large B cell or grade IIIb follicular lymphoma, either at 
diagnosis (15 patients) or relapsed (5 patients), were prospectively enrolled.  
Thirteen out of 20 NHL patients (65%) had a complete response (CR) and an additional 5 
patients (25%) achieved a partial response (PR), with an overall response rate of 90% 
(ORR). Notably, the median age of the study population (73 years) was the oldest ever 
reported in literature of patients treated with this combinations. As a matter of fact, this 
population consisted of particularly elderly and frail patients with advanced disease at 
the time of study entry. These patients had indeed an extremely high probability of being 
unable to complete one of the standard anthracyclines-based regimens or to suffer from 
cardiotoxicity. 
The treatment was relatively well-tolerated. Grade 3 or 4 neutropenia occurred in 26% of 
cycles and febrile neutropenia in 5%. There was no significant difference between LVEF at 
baseline, after the 3rd cycle, and at the end of study in 16/19 patients. Notably, 2 patients 
presented a CHF (NYHA 3) after 1 and 3 cycles of R-COMP, respectively and were shifted to 
receive an anthracycline-free regimen while in CR after R-COMP. In these 2 patients, the 
Authors observed a 20% decrease of the LVEF which partially recovered after medical 
therapy. The cumulative percentage of cardiovascular complications was 15%, higher than 
that reported for elderly patients treated with R-CHOP 21 or 14. However, this patient 
population consisted only of frail patients having a poor WHO performance status and 
important comorbidities.  
This study demonstrated for the first time the safety and efficacy of the R-COMP 21 regimen 
in frail and elderly patients with aggressive NHL. Cardiotoxicity was low and a promising 
response rate was observed in this setting patients.  
Another interesting study regarding the safety and the efficacy of the R-COMP combination 
was recently published (Luminari et al., 2010). Seventy-five elderly patients with diffuse 
large B-cell lymphoma (DLBCL) were studied. Only patients with left ventricular ejection 
fraction (LVEF) > or =50% were allowed. R-COMP regimen was administered every 3 weeks 
for three cycles, followed by additional five cycles in case of complete response (CR) or 
partial response. 
Seventy-five patients with a median age of 72 years were registered, and 72 were 
evaluable for response assessment.  Fifty-six percent of patients had high or high-
intermediate International Prognostic Index score. Median LVEF at baseline was 61%. 
Thirty-eight patients had history of abnormal cardiovascular conditions. The overall 
response rate was 71%, with a CR rate of 57%. After a median follow-up of 33 months, the 
3-year overall survival, failure-free survival, and progression-free survival rates were 
72%, 39%, and 69%, respectively. Neutropenia (54%) was the most frequent grade 3-4 
adverse event; 21% of patients experienced cardiac adverse events, graded as 3-4 in 4% of 
the cases.  
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8. Pegylated Liposomal Doxorubicin (PLD) 
Pegylated liposomal doxorubicin (PLD) is doxorubicin confined in liposomes that have been 
sterically stabilized by grafting polyethylene glycol onto the surface (Stealth Liposome“). 
PLD has a circulation half-life of approximately 73.9 h, whereas doxorubicin has a half-life 
of <10 min. Prolonged circulation facilitates greater uptake of PLD liposomes by tumor 
tissue. PLD accumulates selectively in metastatic breast carcinoma tissue, resulting in 10-
fold higher intracellular drug concentrations compared with adjacent normal tissue (Symon 
et al., 1999). Pegylated liposomal encapsulation also reduces plasma levels of free 
doxorubicin and may reduce drug delivery to normal tissue, which may reduce toxicity. 
Studies of PLD suggest that a dose of 45 to 50 mg/m2 every 4 weeks is well tolerated with 
little nausea or vomiting, mild myelosuppression, minimal alopecia, and very little 
cardiotoxicity. 
8.1 Pegylated liposomal doxorubicin in breast cancer 
The first randomized, multicenter, phase III study was designed to demonstrate that 
efficacy  in terms of progression-free survival of pegylated liposomal doxorubicin HCl 
(PLD) was non-inferior to doxorubicin with significantly less cardiotoxicity in first-line 
treatment of women with metastatic breast cancer (MBC) (O’Brien et al., 2004). Women (n 
= 509) with MBC and normal cardiac function were randomized to receive either PLD 50 
mg/m2 (every 4 weeks) or doxorubicin 60 mg/m2 (every 3 weeks). Cardiac event rates 
were based on reductions in left ventricular ejection fraction as a function of cumulative 
anthracycline dose. 
In this open-label, multicenter trial, patients were randomized in a 1:1 ratio by an 
independent central third party according to a computer-generated randomization 
program. Patients received either PLD [50 mg/m2 intravenous (i.v.) infusion for up to 60 
min every 4 weeks] or doxorubicin [60 mg/m2 i.v. infusion for 60 min every 3 weeks]. 
Patients were prospectively stratified based on three criteria to balance major prognostic 
risk factors between treatment groups: prior adjuvant anthracycline exposure; presence 
of bone metastases as only site of disease;  presence of at least one cardiac risk factor 
(O’Brien et al., 2004).  Cardiac risk factors were defined as prior mediastinal irradiation, 
age ≥65 years, history of heart disease (previous myocardial infarction, arrhythmia or 
angina, not requiring treatment) or hypertension, or diabetes requiring medical 
treatment. 
Regarding cardiotoxicity, MUGA scans were performed to measure LVEF before onset of 
treatment, after 300 mg/m2 cumulative anthracycline exposure, and after every additional 
100 mg/m2 of PLD and every 120 mg/m2 of doxorubicin. Compliance with the protocol on 
performing MUGA evaluations was high. Of the 283 patients who reached doses ≥300 
mg/m2 cumulative anthracyclines, all but 20 patients (nine PLD, 11 doxorubicin) had a 
baseline MUGA evaluation and at least one follow-up MUGA evaluation during treatment 
(O’Brien et al., 2004).  
Overall, 339 patients (152 PLD and 187 doxorubicin) had electronic MUGA scan data for 
evaluation of cardiotoxicity (baseline and at least one scan during treatment) and were 
included in the analysis. Patients in the PLD arm had a median cumulative anthracycline 
dose of 398 mg/m2 (including prior anthracycline exposure). Patients in the 
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conventional doxorubicin arm had a median cumulative anthracycline dose of 421 
mg/m2 (including prior anthracycline exposure). Fifty-eight patients (10 PLD, 48 
doxorubicin) met the protocol-defined LVEF criteria for cardiotoxicity during treatment 
and/or follow-up. The risk of developing cardiotoxicity was significantly higher for 
patients receiving doxorubicin than for those receiving PLD (P <0.001, HR = 3.16 for 
comparison of cumulative anthracycline dose at the first, protocol-specified, cardiac 
event) (O’Brien et al., 2004). The increase in risk of developing cardiotoxicity on 
doxorubicin versus PLD was observed in all subgroups analyzed, including those at high 
risk for developing CHF. In the subgroup that received prior adjuvant anthracycline 
therapy, the risk of developing cardiotoxicity was seven-fold higher with doxorubicin 
than with PLD. None of the 10 PLD-treated patients who had cardiotoxicity by LVEF 
criteria developed clinical signs or symptoms of CHF, whereas 10 of 48 doxorubicin-
treated patients who had cardiotoxicity by LVEF criteria developed signs or symptoms 
of CHF. Two patients in each group developed clinical CHF but did not have a 
corresponding decrease in LVEF. As expected with doxorubicin, the mean percentage 
change from baseline in LVEF was positively correlated with the increase in cumulative 
anthracycline dose. However, with PLD, only a 2–3% mean decrease in LVEF was 
observed as the cumulative anthracycline dose increased. At cumulative doses at or 
above 450 mg/m2, a seven-fold greater mean percentage decrease in LVEF was observed 
with doxorubicin versus PLD (–17.2% versus– 2.3%; mean percentage change from 
baseline in LVEF in doxorubicin-treated and PLD-treated patients, respectively) (O’Brien 
et al., 2004). 
Regarding efficacy, PLD and doxorubicin were comparable with respect to PFS (6.9 versus 
7.8 months, respectively) and to OS (21 and 22 months for PLD and doxorubicin, 
respectively. Palmar-plantar erythrodysesthesia (48% versus 2%), stomatitis (22% versus 
15%) and mucositis (23% versus 13%) were more often associated with PLD than 
doxorubicin. In conclusion, in first-line therapy for MBC, PLD provides comparable efficacy 
to doxorubicin, with significantly reduced cardiotoxicity (O’Brien et al., 2004). 
Another multicentric, randomized trial was published on the same year (Keller et al., 2004). 
This trial was designed to compare the efficacy of pegylated liposomal doxorubicin (PLD) 
with that of a common salvage regimen (comparator) in patients with taxane-refractory 
advanced breast cancer. Following failure of a first- or second-line taxane-containing 
regimen for metastatic disease, 301 women were randomly assigned to receive PLD (50 
mg/m2 every 28 days); or comparator-vinorelbine (30 mg/m2 weekly) or mitomycin C (10 
mg/m2 day 1 and every 28 days) plus vinblastine (5 mg/m2 day 1, day 14, day 28, and day 
42) every 6 to 8 weeks (Keller et al., 2004). Changes in LVEF values were only assessed in 
patients receiving PLD. Cardiac toxicity was defined as either a decrease of ≥ 15 points from 
baseline or a ≥ 5-point decrease from baseline with a level below the lower limit of normal 
for the institution. Twenty-two patients developed LVEF changes consistent with cardiac 
toxicity. However, decreases in LVEF did not correlate with cumulative anthracycline dose 
and none of these patients developed clinical congestive heart failure. The majority (n = 14) 
discontinued due to progressive disease. There were four patients who discontinued 
treatment due to cardiac toxicity (LVEF decrease), three patients who discontinued due to 
noncardiac adverse events, and one patient who discontinued due to noncompliance. 
Progression-free survival (PFS) and overall survival (OS) were similar for PLD and 
comparator (Keller et al., 2004). 
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8.2 Pegylated liposomal doxorubicin in non-Hodgkin lymphoma 
Pegylated liposomal doxorubicin has been substituted for conventional doxorubicin in the 
CHOP regimen in a number of trials. In phase II studies in elderly patients with diffuse 
large B-cell lymphoma, ORR of approximately 65% was achieved: 50% CR and 15% PR, an 
estimated 1-year OS of 55%, and an estimated 2-year event-free survival of 45%. 
Neutropenia was the only grade III-IV toxicity observed [23,24].  
Cutaneous T-cell lymphoma (CTCL) is a specific niche in which PLD has proven to be very 
active at low doses in a similar fashion to Kaposi sarcoma [25]. A response rate of 88% (44% 
CR) with mean OS of 18 months was observed in a retrospective analysis of 31 patients 
receiving PLD at doses varying from 20-40 mg/m2 every 4 weeks. These patients had 
recurrent or unresponsive disease, or rapidly progressive disease [25]. 
Indeed, PLD has been shown to have equal efficacy and a better safety profile in the 
treatment of multiple myeloma, when compared with conventional doxorubicin 
combinations. In controlled clinical trials, PLD combined with vincristine and 
dexamethasone provided response rates comparable with the doxorubicin-based standard 
vincristine/doxorubicin/dexamethasone) therapy, but the former required less 
hospitalization, no central venous catheter, with a reported lower toxicity in terms of 
alopecia and severe leukopenia [26]. There are ongoing studies trying to establish the 
usefulness of newer compounds in combination with liposomal anthracyclines for the 
therapy of multiple myeloma. 
9. Conclusions 
New acquisitions, particularly in terms of pathogenetical mechanisms, have considerably 
changed the perception of anthracycline cardiotoxicity in patients cured after a cancer 
diagnosis. From a " cumulative dose" era, where caution to further treatments with 
anthracyclines was linked more to a mere calculation of global administered dose, we are 
now shifting to a more prudential approach, that considers a persistent biological damage 
due to anthracycline administration, and prompts us toward a better definition of 
measures able to control, in particular, late cardiac toxicity. One item is becoming evident: 
a strict cohoperation between cardiologists and oncologists/hematologists could 
significantly improve the life expectancy and reduce the risks of major CHF in 
anthracycline pretreated patients, simply not underevaluating concurrent risk factors for 
CHF, that must be addressed early and consistently with adequate "cardiological" 
therapies.  
On the other hand, the pharmacological research has in some way met the challenge to 
reduce the toxicity of the therapy with anthracyclines, both designing new, safer, 
anthracycline analogues, such as liposomal compounds, and reshaping the way to use 
protective compounds, such as dexrazoxane, during anthracycline therapy. The possible 
role (and optimal way of use) of iron chelators, such as deferasirox, is still under 
evaluation.  
Cost related issues have up to now limited the use of liposomal derivatives, except for 
niches of fragile patients; it should be considered, anyway, if the global,high impact on costs 
of cardiotoxicity in cancer survivors(in terms of disability and related treatments) could 
justify,expecially in the long run, the costs of an optimized treatment,with modified 
anthracyclines or with cardioprotectants, potentially able to reduce, in particular, the 
frequency of late cardiac toxicity. 
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